Skip to content

Search

New funding to tackle undiagnosed diseases and improve cancer immunotherapy

One of the researchers who helped crack the code of 10-year-old Northam girl Charlotte Patterson’s incredibly rare disease has received State Government funding that will allow her to use the same methods to rapidly assess the cases of hundreds more patients living with undiagnosed disease.

Pioneering new treatments for leukaemia in children with Down syndrome

A team of world-leading scientists has secured $5 million in funding from the Leukaemia and Lymphoma Society to advance the fight against leukaemia in children with Down syndrome.

Brain Cancer Awareness Month Q&A: Dr Hetal Dholaria’s vital work for WA Kids

Each year in Australia, around 120 children are diagnosed with brain cancer, the leading cause of cancer-related death in young people.

Big run ends, race for cure continues

Our local legend, brain cancer researcher Jacob Byrne, has crossed the finish line of his final marathon, completing his Big Run for Little Brains - 30 marathons in 30 days, covering 1266km across Perth’s local government areas.

Rare case of spontaneous simultaneous extensive subcutaneous emphysema, bilateral pneumothoraces, pneumomediastinum and pneumorrhachis

Nick Gottardo MBChB FRACP PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

Our study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia

Genome-wide association meta-analysis of single-nucleotide polymorphisms and symptomatic venous thromboembolism during therapy for ALL and lymphoma in caucasian children

The largest GWAS meta-analysis conducted to date associating SNPs to venous thromboembolism in children and adolescents treated on childhood ALL protocols

Bilateral murine tumor models for characterizing the response to immune checkpoint blockade

This protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade

Diverse Anti-Tumor Immune Potential Driven by Individual IFNα Subtypes

Our data shows that the expression of distinct IFNα subtypes within the tumor microenvironment results in different anti-tumor activities

Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia

The aim of our study was to investigate whether CBL0137 has potential as a therapeutic and chemopotentiating compound in MLL-r leukemia